STML - How Stemline's Latest Catalyst Shifts The Investment Thesis
2018 has been no stranger to exciting developments in biotech, what with the first approvals for RNAi technology, emerging gene therapies, and treatment options for rare forms of cancer.
In particular, for me, it's been a banner year for several companies going it on their own in the development of key cancer drugs. Stakeholders of Progenics (PGNX) and Agios (AGIO), in particular, have seen some nice returns. Today, I want to focus on Stemline Therapeutics (STML), updating on some dusty thoughts of mine from 2016.
Notably, STML recently